JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $300
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $285 to $300.
JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $285 to $300.
More on JNJ
Benzinga
Congressman Dumps Stocks for Treasury Note: Is This a Warning Sign?A recent trade by a member of Congress could signal a preference for Treasuries over stocks, which could be a trade to watch.

Benzinga
Johnson & Johnson’s Phase 4 STAR Study Of TREMFYA Meets Met Primary And Major Secondary Endpoints In Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial InvolvementTREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4…
